Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT

Detalles Bibliográficos
Autores principales: Yang, Yingying, Hu, Yongxian, Huang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society for Regenerative Medicine 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646647/
https://www.ncbi.nlm.nih.gov/pubmed/31367654
http://dx.doi.org/10.1016/j.reth.2019.06.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646647/
https://www.ncbi.nlm.nih.gov/pubmed/31367654
http://dx.doi.org/10.1016/j.reth.2019.06.006

Ejemplares similares